Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 18Smoldering Multiple Myeloma 2Hematologic Neoplasms 2Recurrence 1Lymphoma 1Leukemia, Plasma Cell 1

Interventions

Melphalan 5fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclophosphamide 3Tacrolimus 2pomalidomide 1ixazomib 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1Stem Cell Transplantation 1Sirolimus 1Panobinostat 1Lenalidomide 1High-Throughput Screening Assays 1Gemcitabine 1Filgrastim 1Etoposide 1Dexamethasone 1Cytarabine 1Carmustine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Plasma Cell × elotuzumab × Clear all
NCT01729091 2025-05-09

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
72 enrolled 14 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡